Systemic Finafloxacin

About MerLion Pharmaceuticals

MerLion Pharmaceuticals, founded in 2002 and headquartered in Berlin, Germany, is a clinical-stage biopharma company addressing antimicrobial resistance and biodefense needs. Its lead candidate, finafloxacin, is a differentiated fluoroquinolone with an approved otic formulation (Xtoro™) and promising systemic applications in complicated urinary tract infections (cUTI) and against Category A/B biothreat agents like those causing melioidosis and plague. The company is privately held, has secured non-dilutive funding from defense agencies, and is advancing its pipeline through strategic partnerships with government bodies.

About MerLion Pharmaceuticals

MerLion Pharmaceuticals, founded in 2002 and headquartered in Berlin, Germany, is a clinical-stage biopharma company addressing antimicrobial resistance and biodefense needs. Its lead candidate, finafloxacin, is a differentiated fluoroquinolone with an approved otic formulation (Xtoro™) and promising systemic applications in complicated urinary tract infections (cUTI) and against Category A/B biothreat agents like those causing melioidosis and plague. The company is privately held, has secured non-dilutive funding from defense agencies, and is advancing its pipeline through strategic partnerships with government bodies.

About MerLion Pharmaceuticals

MerLion Pharmaceuticals, founded in 2002 and headquartered in Berlin, Germany, is a clinical-stage biopharma company addressing antimicrobial resistance and biodefense needs. Its lead candidate, finafloxacin, is a differentiated fluoroquinolone with an approved otic formulation (Xtoro™) and promising systemic applications in complicated urinary tract infections (cUTI) and against Category A/B biothreat agents like those causing melioidosis and plague. The company is privately held, has secured non-dilutive funding from defense agencies, and is advancing its pipeline through strategic partnerships with government bodies.

Therapeutic Areas